Pfizer Invests $100 Million To Expand Singapore Nutrition Plant
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Pfizer has invested $100 million in its Singapore nutrition factory, increasing its production capacity by 50 percent, as the company eyes infant nutrition opportunities in Asia
You may also be interested in...
Amid Speculation On Downsizing In India, Pfizer And Wyeth Add Staff, Create More Positions For Women
MUMBAI - Pfizer India head Kewal Handa might be faced with a peculiar situation - that of recruiting hundreds of additional staff while his counterparts are given a rather awkward task of cutting employees who have become redundant due to the duplication of portfolios
Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma
TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines
Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth
SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group